Login / Signup

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.

Yaseen M ArabiAnthony C GordonLennie P G DerdeAlistair D NicholSrinivas MurthyFarah Al BeidhDjillali AnnaneLolowa Al SwaidanAbi BeaneRichard BeasleyLindsay R BerryZahra BhimaniMarc J M BontenCharlotte A BradburyFrank M BrunkhorstMeredith BuxtonAdrian BuzgauAllen ChengMenno De JongMichelle A DetryEamon J DuffyLise J EstcourtMark FitzgeraldRob FowlerTimothy D GirardEwan C GoligherHerman GoossensRashan HaniffaAlisa M HigginsThomas E HillsChristopher M HorvatDavid T HuangAndrew J KingFrancois LamontagnePatrick R LawlerRoger LewisKelsey LinstrumEdward LittonElizabeth LorenziSalim MalakoutiDaniel F McAuleyAnna McGlothlinShay McguinnessBryan J McVerryStephanie K MontgomerySusan C MorpethPaul R MounceyKatrina OrrRachael ParkeJane C ParkerAsad E PatanwalaKathryn M RowanMarlene S SantosChristina T SaundersChristopher W SeymourManu Shankar-HariSteven Y C TongAlexis F TurgeonAnne M TurnerFrank Leo Van de VeerdonkRyan ZarychanskiCameron GreenScott BerryJohn C MarshallColin McArthurDerek C AngusSteven A Webbnull null
Published in: Intensive care medicine (2021)
Among critically ill patients with COVID-19, lopinavir-ritonavir, hydroxychloroquine, or combination therapy worsened outcomes compared to no antiviral therapy.
Keyphrases
  • combination therapy
  • randomized controlled trial
  • antiretroviral therapy
  • study protocol
  • systematic review
  • type diabetes
  • clinical trial
  • mesenchymal stem cells
  • metabolic syndrome
  • insulin resistance